Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) EBT (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed EBT for 11 consecutive years, with -$2.0 million as the latest value for Q3 2025.

  • On a quarterly basis, EBT rose 13.41% to -$2.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$14.4 million, a 817.12% decrease, with the full-year FY2024 number at -$10.7 million, up 23.93% from a year prior.
  • EBT was -$2.0 million for Q3 2025 at Marker Therapeutics, up from -$4.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $8.9 million in Q4 2023 to a low of -$10.9 million in Q2 2021.
  • A 5-year average of -$4.4 million and a median of -$4.1 million in 2023 define the central range for EBT.
  • Biggest YoY gain for EBT was 403.73% in 2023; the steepest drop was 274.22% in 2023.
  • Marker Therapeutics' EBT stood at -$9.8 million in 2021, then skyrocketed by 70.0% to -$2.9 million in 2022, then skyrocketed by 403.73% to $8.9 million in 2023, then plummeted by 142.57% to -$3.8 million in 2024, then soared by 47.23% to -$2.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's EBT are -$2.0 million (Q3 2025), -$4.1 million (Q2 2025), and -$4.4 million (Q1 2025).